ArticleCancers2019
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Exome sequencing points to pathogenic ATM variants in gastric cancer.European journal of human genetics : EJHG · 2026Article
- Integrative bioinformatics analyses identify EDNRA and BCL2L1 as candidate hub genes linking predicted MEHP targets and gastric cancer.Discover oncology · 2026Article
- Multigene Germline Panel Testing in Gastric Cancer Patients in a Portuguese Population.Cancer medicine · 2026Observational
- Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients.International journal of cancer · 2025Article
- The role of multi-organ cancer predisposition genes in the risk of inherited and histologically diverse gastric cancer.EBioMedicine · 2025Article
- Marginal Contribution of PathogenicJournal of cancer & allied specialties · 2024Article
- Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer.Discover oncology · 2023Article
- CDH1 mutations recurrence and global clustering in genetically tested families with hereditary diffuse gastric cancer syndrome: results from a systematic study.Familial cancer · 2023Article
- Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes.Frontiers in oncology · 2022Article
- Clinical, Molecular and Genetic Characteristics of Early Onset Gastric Cancer: Analysis of a Large Multicenter Study.Cancers · 2021Article
- Genetic and Epigenetic Alterations ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Disease spectrum of gastric cancer susceptibility genes.Medical oncology (Northwood, London, England) · 2021Article
- Geographical Distribution of E-cadherin Germline Mutations in the Context of Diffuse Gastric Cancer: A Systematic Review.Cancers · 2021Review
- Hydrogen inhibits the proliferation and migration of gastric cancer cells by modulating lncRNA MALAT1/miR-124-3p/EZH2 axis.Cancer cell international · 2021Article
- Family's History Based on theInternational journal of molecular sciences · 2020Article
- Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients.Diagnostics (Basel, Switzerland) · 2020Article
- Article
- Molecular characteristics of synchronous multiple gastric cancer.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 2 countries.
Gianluca TedaldiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. gianluca.tedaldi@irst.emr.it.ORCID 0000-0003-0540-6694
Francesca PiriniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. francesca.pirini@irst.emr.it.ORCID 0000-0002-7629-2439
Michela TebaldiBiostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. michela.tebaldi@irst.emr.it.ORCID 0000-0003-0717-2748
Valentina ZampigaBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. valentina.zampiga@irst.emr.it.
Ilaria CanginiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. ilaria.cangini@irst.emr.it.ORCID 0000-0002-1739-6916
Rita DanesiRomagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. rita.danesi@irst.emr.it.
Valentina ArcangeliDepartment of Medical Oncology, Ospedale Infermi, 47923 Rimini, Italy. valentina.arcangeli@auslromagna.it.
Mila RavegnaniRomagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. mila.ravegnani@irst.emr.it.
Raefa Abou KhouzamDepartment of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy. raefa.aboukhouzam01@universitadipavia.it.
Chiara MolinariBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. chiara.molinari@irst.emr.it.ORCID 0000-0003-1011-5656
Carla OliveiraInstitute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. carlaol@ipatimup.pt.ORCID 0000-0001-8340-2264
Paolo MorgagniDepartment of General Surgery, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy. morgagni2002@libero.it.ORCID 0000-0002-1564-2415
Luca SaragoniPathology Unit, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy. luca.saragoni@auslromagna.it.ORCID 0000-0002-2137-9596
Maria BencivengaUnit of Upper GI Surgery, University of Verona, 37126 Verona, Italy. mariabenci@hotmail.it.
Paola UliviBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. paola.ulivi@irst.emr.it.
Dino AmadoriDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. dino.amadori@irst.emr.it.
Giovanni MartinelliDepartment of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. giovanni.martinelli@irst.emr.it.
Fabio FalciniRomagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. fabio.falcini@irst.emr.it.
Guglielmina Nadia RanzaniDepartment of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy. guglielmina.ranzani@unipv.it.ORCID 0000-0002-3080-6473
Daniele CalistriBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy. daniele.calistri@irst.emr.it.ORCID 0000-0002-5064-2023
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale G.B. Morgagni - L.Pierantoni · ITUniversity of Pavia · ITOspedale Infermi di Rimini · ITUniversidade do Porto · PTUniversity of Verona · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main gene involved in gastric cancer (GC) predisposition is
Indexed as
cancer predispositionCDH1 genenext-generation sequencingstomach neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.